At 100 μg/ml, D-LL-37 also elicited no significant hemolysis and was not statistically significantly different than the GSK2118436 supplier L-form (p = 0.29 compared to LL-37). 2.3 Inhibition of biofilm BI-D1870 in vivo formation at sub-anti-microbial concentrations Another common concern of the utility of antimicrobial peptides as potential therapeutics is the sensitivity of the antimicrobial activity to salt. Multiple studies have shown that LL-37 demonstrates reduced antimicrobial action in environments with high ionic concentrations [30, 31] such as in physiologic salt concentration (123-150 mM NaCl). However,

LL-37 can inhibit biofilm formation by P. aeruginosa [32], S. epidermidis [33] and F. novicida [25] in media with a high concentrations of salt. In conclusion, although the LL-37 peptide loses its anti-microbial activity in high salt, it retains its anti-biofilm activity. In this study, we demonstrate similar salt-independent

anti-biofilm activity for NA-CATH, NA-CATH:ATRA1-ATRA1 and D-LL-37 peptides. We incubated various concentrations of NA-CATH, NA-CATH:ATRA1-ATRA1, LL-37, D-LL-37, and scrambled LL-37 with S. aureus in biofilm experiments in sterile TSB (relatively high salt) for 24 h. Figure 2 (2a, b, c, d and 2e) shows that levels of bacterial growth (OD600 at 24 hours) were not decreased even at the peptide concentrations equal to that of its selleck chemicals llc calculated EC50 in sterile 10 mM sodium phosphate. The MIC of LL-37 against S. aureus was determined to be >400 μg/ml, in TSB (data not shown). When the biofilm production was determined in the presence of varying amounts of peptide, significant inhibition of biofilm formation by each of the peptides (except the scrambled LL-37) was observed at concentrations in which no anti-microbial activity is observed. Thus, wild-type

NA-CATH was found to inhibit biofilm formation up to ~50% of control at 10 μg/ml (Figure 2a). NA-CATH:ATRA1-ATRA1 was found to be the most active anti-biofilm peptide, with maximal biofilm inhibition observed at 1 μg/ml, inhibiting ~60% of biofilm formation (Figure 2b). Figure 2 Anti-biofilm activity of peptides. Inhibition of S. aureus biofilm formation was demonstrated for each of the following peptides. A. NA-CATH. B. NA-CATH:ATRA1-ATRA1. C. LL-37. D. D-LL-37. E. Scrambled LL-37. Growth (absorbance at 600 nm) is indicated by gray bars with Resveratrol “”0 peptide”" control set to 100%. Biofilm detection on a polystyrene 96-well plate at 37°C after 24 h of growth in TSB was detected as the absorbance of crystal violet stain (570 nm). Percent biofilm production is indicated by black bars (n = 6), relative to “”0 peptide”" control. Each experiment is a representative of at least two independent trials. Error bars indicate the standard deviation from the mean. The asterisk (*) indicates statistically different than the positive control (p < 0.01). For LL-37, significant anti-biofilm inhibition for S.